证券代码：600666 证券简称：奥瑞德 公告编号：临2025-029 奥瑞德光电股份有限公司 关于上海证券交易所对公司2024年年度报告的信息披露监 管工作函的回复公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 奥瑞德光电股份有限公司（以下简称"公司"或"奥瑞德股份"）于近期收到上海证券 交易所下发的《关于奥瑞德光电股份有限公司2024年年度报告的信息披露监管工作函》 （上证公函【2025】0682号）（以下简称"工作函"），现将工作函相关问题回复如下： 一、关于蓝宝石业务 1、关于蓝宝石业务开展情况。年报显示，本年度公司蓝宝石制品实现营收 2.16亿元， 同比微降 1.60%，发生成本 2.03 亿元，蓝宝石制品毛利率上升至 6.14%，同比转正。分 产品来看，蓝宝石晶棒实现营收 3,400.59万元，同比增长 33.22%，蓝宝石晶片实现营收 15,869.18万元，同比下滑 6.21%。请公司：(1)补充披露本年度蓝宝石制造业务前五大客户、 关联关系、所属地区、收入确认金额、产品类型、是否属于本年新增客户或供应商 ...

New Stock Offerings - Jichuan Pharmaceutical (600566) has a tender offer period from June 18, 2025, to July 17, 2025[1] - *ST Yazhen (603389) has a tender offer period from June 10, 2025, to July 9, 2025[1] - Zhongcheng Tui (300208) has 11 trading days remaining until the last trading day[1] Delisting and Trading Reminders - Tui Shi Jin Gang (600190) has 11 trading days remaining until the last trading day[1] - Hengli Tui (000622) is in the delisting arrangement period with 8 trading days remaining[1] - Tui Shi Jiu You (600462) has 7 trading days remaining until the last trading day[1] Market Volatility - Beifang Changlong (301357) reported severe abnormal fluctuations[1] - Multiple companies, including Jichuan Pharmaceutical and *ST Yazhen, are under scrutiny for trading anomalies[1]

Core Viewpoint - The stock of Aorede (600666) experienced a significant decline of 8.61% on the trading day, with a turnover rate of 21.51% and a total transaction value of 1.774 billion yuan, indicating high volatility and trading activity [2]. Trading Activity - The stock was listed on the Shanghai Stock Exchange due to a daily price deviation of -9.00%, with a net buying amount from brokerage seats totaling 78.6188 million yuan [2]. - The top five brokerage seats accounted for a total transaction value of 350 million yuan, with a buying transaction value of 214 million yuan and a selling transaction value of 135 million yuan, resulting in a net buying of 78.6188 million yuan [2]. - The largest buying brokerage was Goldman Sachs (China) Securities, which purchased 57.9284 million yuan, while the largest selling brokerage was East Asia Qianhai Securities, which sold 48.8010 million yuan [2]. Fund Flow - The stock saw a net outflow of 145 million yuan in main funds, with a significant outflow of 133 million yuan from large orders and 12.2697 million yuan from medium orders. Over the past five days, the net outflow of main funds reached 38.6727 million yuan [2]. Financial Performance - Aorede's Q1 financial report revealed that the company achieved an operating income of 98.3838 million yuan, representing a year-on-year growth of 12.74%. However, the net profit was reported at -8.3320 million yuan [2].

New Stock Issuance - The new stock "同宇新材" (code: 301630) is listed at an issuance price of 84.00[1] - "信通电子" (code: 001388) has an issuance price of 16.42[1] Rights Issues and Announcements - "济川药业" (code: 600566) has a tender offer period from June 18, 2025, to July 17, 2025[1] - "中程退" (code: 300208) has 13 trading days remaining until the last trading day[1] - "退市锦港" (code: 600190) also has 13 trading days remaining until the last trading day[1] - "恒立退" (code: 000622) has 10 trading days remaining until the last trading day[1] Abnormal Fluctuations - "浙江东日" (code: 600113) reported severe abnormal fluctuations[1] - "汇金股份" (code: 300368) is noted for abnormal fluctuations[3]

Core Viewpoint - The company has experienced abnormal stock trading fluctuations, with a cumulative closing price increase of 20% over three consecutive trading days, prompting the need for disclosure and clarification regarding its operational status and any undisclosed significant information [1][4]. Group 1: Company Operational Status - The company and its subsidiaries are operating normally, with no significant changes in the market environment or industry policies [2]. - The company has confirmed with its controlling shareholder, Qingdao Zhican, that there are no undisclosed significant matters, including major asset restructuring or significant transactions [2][3]. - No media reports or market rumors have been identified that could impact the company's stock trading price [2]. Group 2: Risks and Uncertainties - The company is investing in a computing power service business, which involves substantial capital investment and is subject to various uncertainties, including macroeconomic conditions and industry competition [3]. - There is uncertainty regarding the performance of compensation obligations due to the judicial freeze on shares held by key individuals, which may affect the company's ability to recover compensation [3][4]. - Financial investors have significantly reduced their holdings, with a total of 962,311,324 shares sold, representing 81.80% of their previously acquired shares, which may continue to impact stock performance [4]. Group 3: Stock Trading Fluctuations - The company's stock experienced a significant price deviation, with a cumulative increase of 20% over three trading days, indicating substantial volatility in the secondary market [1][4]. - Investors are advised to exercise caution and make rational investment decisions in light of the observed trading risks [4]. Group 4: Board Statement - The company's board confirms that there are no undisclosed matters that should have been reported according to the relevant stock exchange rules, and all previously disclosed information remains accurate [4].

Core Viewpoint - Multiple listed companies in the Shanghai and Shenzhen stock markets have announced significant updates, including changes in financing, business performance, and strategic decisions, which may impact investor sentiment and market dynamics [1]. Financing and Restructuring - Guanhao Biological has withdrawn its application for refinancing, leading to the termination of the review process by the Shenzhen Stock Exchange [3]. - Jinhongshun has terminated its major asset restructuring plan due to a lack of consensus among parties involved [6]. - Yuyuan Co. plans to issue bonds not exceeding 40 billion yuan to adjust its debt structure and replenish working capital [23]. Business Performance and Uncertainties - Aored has highlighted significant uncertainties in its computing power leasing services due to heavy asset investment and potential market fluctuations [4]. - Guoyao Modern intends to publicly transfer 51% of its subsidiary Guoyao Hason's shares, as the subsidiary has been underperforming with continuous losses since 2021 [5]. - Chengbang Co. reported that its subsidiary, Xinchun Electronics, has a small business scale and faces intense competition in the semiconductor storage industry, with projected revenues of 111 million yuan and a net profit of 933,800 yuan for 2024 [9]. Stock Market Activity - Alloy Investment announced a change in its controlling shareholder to Jiuzhou Hengchang, with stock trading resuming on July 1 [7]. - Changcheng Military Industry reported significant stock price volatility, with a cumulative increase of over 100% in the last 10 trading days, indicating potential irrational market behavior [8]. Earnings Forecasts - Hanyu Pharmaceutical expects a net profit of 142 million to 160 million yuan for the first half of 2025, recovering from a loss in the previous year, driven by international business growth [12]. - Taotao Vehicle anticipates a net profit increase of 70.34% to 97.81% for the same period, reflecting strong sales performance [13]. - Weichai Heavy Machinery projects a net profit increase of 40% to 60%, benefiting from industry policy support and demand growth [15]. Major Contracts and Projects - China Railway has won contracts for overseas construction projects totaling approximately 5.343 billion yuan [17]. - Zhonggong International has signed a 175 million yuan engineering consulting service contract [18]. - Hezhan Energy has entered into a 177 million yuan contract for the sale of steel-concrete towers [19].

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 1、奥瑞德光电股份有限公司（以下简称"公司"）股票交易于 2025 年 6 月 26 日、 2025 年 6 月 27 日、2025 年 6 月 30 日连续三个交易日内日收盘价格涨幅偏离值累计达 20%，根据《上海证券交易所交易规则》的有关规定，属于股票交易异常波动的情形。 2、经自查，公司及子公司生产经营正常，未发生其他重大变化，所处市场环境、 行业政策未发生重大调整。经公司董事会自查并向公司控股股东青岛智算信息产业发 展合伙企业（有限合伙）（以下简称"青岛智算"）函证，除已披露的事项外，截至 本公告披露之日，公司及公司控股股东青岛智算不存在应披露而未披露的重大信息。 3、算力综合服务业务风险：公司算力综合服务业务可能受宏观经济及行业政策变 化、公司运营人才及业务经验等因素的影响，业绩存在重大不确定性，请投资者注意 相关业务业绩风险。 证券代码：600666 证券简称：奥瑞德 公告编号：临2025-028 奥瑞德光电股份有限公司 股票交易异常波动公告 个交易日 ...

Group 1 - The company, Aorede (600666), has announced unusual fluctuations in its stock trading, indicating potential volatility in its market performance [1] - The company provides computing power leasing services and charges fees for these services, which require significant capital investment [1] - The pricing of computing power leasing services may be influenced by various uncertain factors, including macroeconomic conditions, industry policies, technological advancements, and market competition, leading to substantial uncertainty in performance [1]

证券代码：600666 证券简称：奥瑞德 公告编号：临 2025-027 奥瑞德光电股份有限公司 2024年年度股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东会召开的时间：2025 年 6 月 27 日 (二)股东会召开的地点：北京市海淀区知春路 68 号领航科技大厦 11 层西侧北京 智算力数字科技有限公司 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 40 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 585,692,080 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 21.4713 | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次会议由公司董事会召集，公司董事长朱三高先生主持会议。本次会议的 (一)非累积投票议案 1、 议案名称：公司 ...

德和衡证见意见（2025）第00149号 北京德和衡律师事务所 关于奥瑞德光电股份有限公司 2024年年度股东会的 法律意见书 中国·北京市朝阳区建国门外大街 2 号银泰中心 C 座 11、12 层 电话：(+8610)85407666 邮编：100022 网址：www.deheheng.com 中国北京市朝阳区建国门外大街 2 号北京银泰中心 C 座 11 层、12 层 Tel：(+8610)85407666 邮编：100022 www.deheheng.com 北京德和衡律师事务所 关于奥瑞德光电股份有限公司 2024年年度股东会的 法律意见书 德和衡证见意见（2025）第00149号 致：奥瑞德光电股份有限公司 北京德和衡律师事务所（以下简称"本所"）接受奥瑞德光电股份有限公司 （以下简称"公司"）的委托，指派本所律师出席公司 2024 年年度股东会（以 下简称"本次股东会"），本所律师根据《中华人民共和国公司法》（以下简称 "《公司法》"）、《上市公司股东会规则》（以下简称"《股东会规则》"）、 《奥瑞德光电股份有限公司章程》（以下简称"《公司章程》"）以及其他相关 法律、法规、规范性文件，就本次股东 ...